Drug repurposing against coronavirus disease 2019 (COVID-19): A review.

Abstract

Since December 2019, severe acute respiratory syndrome coronavirus 2 has been found to be the culprit in the coronavirus disease 2019 (COVID-19), causing a global pandemic. Despite the existence of many vaccine programs, the number of confirmed cases and fatalities due to COVID-19 is still increasing. Furthermore, a number of variants have been reported. Because of the absence of approved anti-coronavirus drugs, the treatment and management of COVID-19 has become a global challenge. Under these circumstances, drug repurposing is an effective method to identify candidate drugs with a shorter cycle of clinical trials. Here, we summarize the current status of the application of drug repurposing in COVID-19, including drug repurposing based on virtual computer screening, network pharmacology, and bioactivity, which may be a beneficial COVID-19 treatment.

• Authors: Lianxiang Luo, Qin Qiu, Fangfang Huang, Kaifeng Liu, Yongqi Lan, Xiaoling Li, Yuge Huang, Liao Cui, Hui Luo
• Journal: Journal of pharmaceutical analysis (J Pharm Anal) Vol. 11 Issue 6 Pg. 683-690 (Dec 2021) ISSN: 2214-0883 [Electronic] China
• PMID: 34513115 (Publication Type: Journal Article, Review)
• Copyright: © 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.